Vimarsana
Biggest News Aggregation in the World

Page 16 - First North News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from First North. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In First North Today - Breaking & Trending Today

Nasdaq Welcomes Marijas 2 to the Baltic First North Market - Vimarsana News

Nasdaq Welcomes Marijas 2 to the Baltic First North Market

Tallinn/Riga/Vilnius, Nasdaq Baltic Market, June 14, 2023 - Nasdaq (Nasdaq: NDAQ) announces that bonds issued by "Marijas 2" have been admitted to trading on the Nasdaq Baltic First North market by Nasdaq

Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares of Binero Group AB (320/23) - Vimarsana News

Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares of Binero Group AB (320/23)

With effect from June 14, 2023, the subscription rights in Binero Group AB will be traded on First North Growth Market. Trading will continue up until and including June 22, 2023. Instrument: Subscription

Nitro Games plans to arrange a rights issue of approximately SEK 77.4 million and secures bridge financing - Vimarsana News

Nitro Games plans to arrange a rights issue of approximately SEK 77.4 million and secures bridge financing

The Board of Directors of Nitro Games Oyj has today decided to arrange a partially secured rights issue of a maximum of 19,354,653 shares , under the condition that the Extraordinary General Meeting... | June 13, 2023

Punktid Technologies : sells own shares - Vimarsana News

Punktid Technologies : sells own shares

Punktid Technologies AS Company Announcement Punktid Technologies AS sells own shares Punktid Technologies AS organises the sale of up to 60,000 own... | June 13, 2023

New biomarker data from BEXMAB study at EHA2023 - Vimarsana News

New biomarker data from BEXMAB study at EHA2023

Faron Pharmaceuticals Oy   Faron Announces New Biomarker Data from Phase I/II BEXMAB Study at EHA2023 Hybrid Congress Bexmarilimab mode of action in AML/MDS supported with durable Clever-1... | June 9, 2023